Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of NeoGenomics, Inc. (NASDAQ:NEO). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in NeoGenomics stock on August 7th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
• Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
• Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
• Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

NeoGenomics Price Performance

NeoGenomics stock opened at $17.32 on Friday. The company’s 50 day simple moving average is $15.91 and its 200-day simple moving average is $11.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.35 and a current ratio of 3.60. NeoGenomics, Inc. has a 1 year low of $7.07 and a 1 year high of $19.76. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -43.30 and a beta of 1.75.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.02. The firm had revenue of $201.66 million for the quarter, compared to analyst estimates of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.NeoGenomics’s revenue was up 11.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.03 EPS. As a group, equities research analysts expect that NeoGenomics, Inc. will post -0.09 earnings per share for the current year.

Hedge Funds Weigh In On NeoGenomics

A number of large investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in NeoGenomics during the second quarter worth $32,000. Caitong International Asset Management Co. Ltd lifted its holdings in NeoGenomics by 110.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 1,556 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of NeoGenomics during the 4th quarter worth $39,000. Smartleaf Asset Management LLC grew its stake in shares of NeoGenomics by 77.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock worth $42,000 after purchasing an additional 1,515 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of NeoGenomics by 113.8% during the 4th quarter. Van ECK Associates Corp now owns 4,921 shares of the medical research company’s stock worth $58,000 after purchasing an additional 2,619 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NEO shares. Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Benchmark upped their price target on NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, July 24th. Craig Hallum reissued a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a report on Wednesday, July 29th. Wall Street Zen upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $17.67.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About NeoGenomics

NeoGenomics, Inc is a provider of cancer-focused diagnostic testing and contract research services. The company operates clinical laboratories that support physicians, hospitals and other healthcare organizations with information used to help diagnose, classify and monitor cancer.

Its testing services include anatomic pathology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular testing and next-generation sequencing. NeoGenomics also provides biopharmaceutical companies with clinical trial testing, central laboratory services, biomarker development and other research services intended to support the development of oncology therapies and companion diagnostics.

Founded in 1999, NeoGenomics serves healthcare providers and pharmaceutical and biotechnology customers primarily in the United States, with additional capabilities supporting international clinical research programs.